Phaseline

Companies › Cullinan Therapeutics

Cullinan Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 7 registered trials: 7 Phase 1; Oncology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CLN-978
CD19-directed T cell engager
CD19Phase 1NHL; SLE; Rheumatoid Arthritis (RA; SjögrenDec 2026
CLN-619
Anti-MICA/MICB monoclonal antibody
MICA, MICBPhase 1Advanced Solid Tumor; Multiple MyelomaMar 2027
CLN-049
FLT3 x CD3 bispecific T cell engager
FLT3, CD3EPhase 1Relapsed/Refractory Acute Myeloid Leukemia (AML)Dec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05879744CLN-978Phase 1NHLOncologyJun 2024
NCT05117476CLN-619Phase 1Advanced Solid TumorOncologyMar 2026
NCT06613360CLN-978Phase 1SLEImmunologyDec 2026
NCT06381141CLN-619Phase 1Multiple MyelomaOncologyMar 2027
NCT06994143CLN-978Phase 1Rheumatoid Arthritis (RAImmunologyDec 2027
NCT07041099CLN-978Phase 1SjögrenImmunologyMar 2028
NCT05143996CLN-049Phase 1Relapsed/Refractory Acute Myeloid Leukemia (AML)OncologyDec 2029

From the company's SEC filings

Cash and short-term investments of $290m on 2026-09-30; operating cash outflow about $171m a year; runway about 20 months at that burn, to Jun 2028

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

FLT3 (1) CD3E (1) CD19 (1) MICA (1) MICB (1)

Companies with the same targets

Bristol-Myers Squibb Roche Johnson & Johnson (Janssen) Gilead Sciences Chongqing Precision Biotech Amgen AstraZeneca Allogene Therapeutics Miltenyi Biomedicine Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.